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Background: Creutzfeldt-Jakob disease and Hashimoto’s encephalopathy often show similar clinical presentation.
Among Creutzfeldt-Jakob disease mimics, Hashimoto’s encephalopathy is particularly important as it is treatable
with corticosteroids. Thus, in cases of middle-aged woman diagnosed with probable Creutzfeldt-Jakob disease
and who exhibit high titers of antithyroid antibodies, corticosteroid pulse therapy is typically performed with
expectations of near complete recovery from Hashimoto’s encephalopathy. Herein, we provide the first case
report that exhibited a negative effect of corticosteroid pulse therapy for a patient with Creutzfeldt-Jakob
disease with features of Hashimoto’s encephalopathy.
Case presentation: We report a case of 59-year-old Asian woman with blurred vision, dysarthria, myoclonus, and
rapidly progressive dementia. Cerebrospinal fluid showed 14-3-3 protein positive. Electroencephalogram showed
periodic sharp waves (1.5 Hz) at the bilateral frontal or occipital areas. Magnetic resonance imaging showed high
signal intensities at the bilateral cerebral cortex, caudate nucleus, and putamen. The patient was diagnosed with
probable Creutzfeldt-Jakob disease. However, serum analysis showed a high titer of antithyroid antibodies. We started
corticosteroid pulse therapy with subsequent aggravation of seizure activity including generalized myoclonus, epilepsia
parialis continua, and ballistic dyskinesia, which was effectively treated with clonazepam.
Conclusion: We provide evidence of a case of Creutzfeldt-Jakob disease that exhibited clinical deterioration
after corticosteroid therapy. Although histopathological confirmation with brain biopsy is not easily available in
Creutzfeldt-Jakob disease patients, selective initiation of corticosteroid pulse therapy should be considered in
cases of uncertain diagnosis for differentiation with Hashimoto’s encephalopathy.
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Creutzfeldt-Jakob disease (CJD) is fatal prion disease
characterized by rapidly progressive dementia, myoclonus,
pyramidal and extrapyramidal signs, visual field defect,
and cerebellar symptoms [1]. Hashimoto’s encephalopathy
is corticosteroid-responsive autoimmune encephalitis with* Correspondence: neuroksy@snu.ac.kr
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unless otherwise stated.antithyroid antibodies that may have overlapping clinical
symptoms with CJD, especially in the early phase of
disease [2]. Hashimoto’s encephalopathy is more common
in female individuals, typically presenting in middle
age with a fluctuating encephalopathy including rapid
progressing dementia, seizure, psychiatric manifestations,
myoclonus, ataxia, stroke-like episodes, and coma, although
the clinical phenotype is variable [3]. Cerebrospinal fluid
(CSF), electroencephalogram (EEG), and brain magnetic
resonance imaging (MRI) findings are non-specific, and
CJD diagnosis is based on an appropriate clinical phenotype
with exclusion of other conditions, in addition to raised. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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anti-thyroid antibodies are not specific to Hashimoto’s
encephalopathy and are common in healthy elderly people
[4]. There is no obvious correlation between antibody
levels and disease severity, and it is likely that the anti-
bodies are not pathogenic but simply an epiphenomenon
reflecting an underlying autoimmune inflammatory state
[5]. Thus, it is widely considered that Hashimoto’s enceph-
alopathy should be relabeled as ‘corticosteroid-responsive
encephalopathy associated with autoimmune thyroiditis’
[6], and that lack of such corticosteroid response should
prompt review of diagnosis [4]. Among CJD mimics,
Hashimoto’s encephalopathy is particularly important as it
is treatable with corticosteroids [7]. In our thorough
review of the literature on CJD mimicking Hashimoto’s
encephalopathy or Hashimoto’s encephalopathy mimicking
CJD, we found no evidence of definite markers for differ-
ential diagnosis of CJD and Hashimoto’s encephalopathy
[2,8-14]. Here, we describe a case of a patient with definite
CJD with high titers of anti-thyroid antibodies whose
clinical symptom was aggravated as a dominant seizure
after initiation of corticosteroid pulse therapy.
Case presentation
A 59-year-old woman was admitted because of blurred
vision, dysarthria, myoclonic movement of bilateral upper
and lower limbs, and rapidly progressive dementia. The
symptoms had started approximately 1 month prior and
progression was so rapid that she became akinetic and
occasionally showed just a slight smile as a response to
questioning over the last 2 weeks.
Her CSF was acellular with no evidence of bacterial or
viral infection, but her 14-3-3 protein was positive. EEG
showed periodic sharp waves (1.5 Hz) at the bilateral
frontal or occipital areas with predominance in the left
side. Contrast-enhanced MRI showed high signal inten-
sities at the bilateral cerebral cortex, caudate nucleus,
and putamen with left predominance (Figure 1). She wasFigure 1 Patient MRI scans. Bilateral high signal intensities in the cortex,diagnosed with probable CJD according to the World
Health Organization diagnostic criteria for sporadic CJD
[15]. Sodium valproate (1200 mg/day) and clonazepam
(0.5 mg/day) were used for intermittent myoclonic jerk.
Laboratory analysis showed high titers of anti-thyroid
peroxidase antibody (TPO-Ab) (1370 IU/mL; normal
value <60 IU/mL) and anti-thyroglobulin antibody
(Tg-Ab) (167 IU/mL; normal value <60 IU/mL). How-
ever, the levels of thyroid-stimulating hormone (2.24 IU/
mL; normal value 0.4–4.0 IU/mL) and FT4 (1.23; normal
value 0.89–1.79) were normal. Follow-up laboratory
study shows persistent high titers of TPO-Ab, while the
titer of Tg-Ab was fluctuating around the normal upper
limit. Thyroid sonography showed no gross abnormality.
Although she was diagnosed as probable CJD, cortico-
steroid pulse therapy with methylprednisolone (1 g per
day) was started on the 6th day of admission for differen-
tial diagnosis with Hashimoto’s encephalopathy, which is
known to show excellent response to corticosteroid ther-
apy. We observed alertness and myoclonic movement
after careful initiation of corticosteroid therapy. Over the
2 days after starting corticosteroid treatment, she was in
a akinetic mute state with no response to pain or visual
response. We also observed two episodes of generalized
clonic movement with eyeball deviation. We elevated
the dose of sodium valproate, titrated to 1800 mg/day,
without subsequent improvement of myoclonic jerk. Her
alertness kept worsening with aggravation of myoclonus,
and she had a first generalized tonic-clonic seizure on the
4th day of corticosteroid therapy. We added levetiracetam
(1000 mg/day) and elevated the dose of sodium valproate
(2400 mg/day). However, the frequency of seizures was
increased and the EEG showed more periodic sharp waves
in the bilateral hemispheres with background slowing
compared with the previous EEG. Generalized myoclonic
movement was observed almost continuously when she
was awake. Thus, we elevated the dose and frequency of
clonazepam, which effectively alleviated the myocloniccaudate nucleus, and putamen on DWI (A) and FLAIR (B).
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tality. As the five days of corticosteroid pulse therapy were
suspected to aggravate the seizures, we performed a brain
biopsy with family consent to confirm a diagnosis of
CJD. Brain biopsy revealed neuronal loss, vacuolation
and gliosis (Figure 2). Western blot demonstrated a
protease-resistant pathogenic form of prion protein in
the brain tissue. Genetic analysis demonstrated no known
mutation in the PRNP gene. A diagnosis of definite CJD
was made based on the above findings.
Discussion
CJD and Hashimoto’s encephalopathy often share similar
clinical features. However, there are no definite markers
for differential diagnosis except for brain biopsy
(Table 1). Clinical manifestation, EEG, brain imaging,
and CSF findings including 14-3-3 protein can overlap
between both disorders. The response to corticosteroid
therapy is generally considered the only effective method
for differential diagnosis before brain biopsy. Thus, in
middle-aged female patients with a high titer of anti-
thyroid antibodies, and who show dementia, myoclonus,
ataxia, and altered consciousness, there is a mandatory
recommendation to start corticosteroid therapy to rule
out Hashimoto’s encephalopathy [2]. Thus, we performed
corticosteroid pulse therapy in our case.
What was unique in our patient is that her myoclonic
seizure was distinctly aggravated as epilepsia partialis
continua and secondary generalized tonic clonic seizure
just after initiation of coritcosteroid pulse therapy. The
semiology of her seizure was composed of mostly multi-
focal myoclonic movement, epilepsia partialis continua, and
ballistic dyskinesia, which showed obvious improvement by
clonazepam in addition to other anti-epileptic drugs. TheA 
C GFAP 
H&E 
Figure 2 Brain biopsy finding of the patient. Spongiform changes with
gliosis in GFAP (C) and positive PrPsc in 3 F4 (D).response to clonazepam was so marked that an elevation of
only 0.25 mg decreased her mentality with subsequent
improvement of myoclonic jerk.
To our knowledge, an aggravated seizure just after ini-
tiation of corticosteroid pulse therapy in definite CJD
has not been previously reported. Although our case was
in a course of deterioration, there was clear temporal
correlation with the initiation of corticosteroid pulse and
abrupt increase in seizure activity. From both acute and
chronic models of epilepsy, there is evidence that high
corticosteroid levels may exacerbate seizure occurrence
[16,17]. Nevertheless, the symptomatology of our patient
cannot be fully explained.
Focal motor or generalized seizures have been reported
in 15–21% of patients with CJD during the later stage of
the disease [18]. However, seizures as the presenting
symptom of CJD are uncommon and occur in only
approximately 3% of cases [19]. Based on five case reports
in the literature, epilepsia partialis continua is reported as
a presenting feature of CJD, although none of those cases
were related to corticosteroid pulse therapy. The irritative,
rather than destructive, nature of the cerebral damage
may be the cause of the continuous jerks [20], while the
loss of basal ganglia influence on the brain stem can also
cause muscular twitches [21]. Our patient also showed
ballistic movement, which was reduced by clonazepam
treatment. Coexistence of generalized chorea and epilepsia
partialis continua as the initial signs was previously re-
ported in probable CJD, although the movement disorder
typically appears during the later disease stage [22].
Conclusion
This is the first definite case of CJD with symptomatic ag-
gravation after corticosteroid pulse therapy for differentialB 
D 3F4 
H&E 
some neuronal cell loss and degeneration in H&E (A, B). Increased
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Table 1 Previously reported cases with the feature of CJD and HE in need of differential diagnosis (Continued)
2004/Sakuria
et al. [11].
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periodic synchronous
discharge
MRI (T2WI): HSI at
periventricular and
basal ganglia lesion









CJD Creutzfeldt-Jakob disease; HE Hashimoto’s encephalopathy; GTC generalized tonic-clonic seizure; DWI diffusion-weighted images; HSI high signal intensity; Tg-Ab anti-thyroglobulin antibody; TPO-Ab anti-thyroid
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http://www.biomedcentral.com/1471-2377/14/179diagnosis with Hashimoto’s encephalopathy. In our patient,
the high titer of anti-thyroid antibodies may have been an
incidental finding, as the thyroid sonography was normal
and brain biopsy confirmed final diagnosis as sporadic
CJD that was abruptly aggravated by corticosteroids.
When a middle-aged woman diagnosed with probable
CJD shows a high titer of anti-thyroid antibodies, cortico-
steroid treatment is typically used as histopathological
confirmation with brain biopsy is not easily available,
with expectations of near complete recovery in cases of
Hashimoto’s encephalopathy. However, if corticosteroid
pulse therapy can cause rapid deterioration or seizure
aggravation of CJD, the use of corticosteroids in probable
CJD patients with high titers of anti-thyroid antibodies
should be cautioned. Our patient showed very typical
clinical symptoms, and EEG, MRI and CSF findings
(14-3-3 protein) of CJD. Thus, it may be reasonable to
selectively start corticosteroid pulse therapy in cases of
uncertain diagnosis. If seizures are aggravated by cor-
ticosteroid treatment, clonazepam may be a good choice
to reduce myoclonic jerk, in addition to anti-epileptic
drugs. Further studies are required to prove a correlation
between corticosteroid treatment and symptomatic aggra-
vation of CJD.
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